Tehran (IP) – Head of clinical studies of the Iranian COVID-19 vaccine said the results of the 'COVIran Barekat' vaccine's first phase of the human trials were auspicious.

Iran Press/Iran News: Mohammad-Reza Salehi stated on Thursday that the results of the serum immunogenicity tests of more than 44 volunteers had been prepared so far, which had been more impressive than expected. 

"Although the results of the first phase of the human trials are auspicious, we have to wait a few more days to determine the safety responses in the tests of all candidates to reach definitive results," he noted. 

He announced that by the end of the Iranian year, the 'COVIran Barekat' vaccine's second phase of human trial would begin. He added that the second phase would be done with the cooperation of some universities of medical sciences in the country. 

He highlighted that this phase's final results would be analyzed in the next few days and would be provided to the Food and Drug Administration and the Health Ministry, which would review the results and approve the permit for the next phase.

Human injection of the first phase of clinical studies of the first Iranian COVID-19 vaccine named 'COVIran Barekat' was commenced on three volunteers on Tuesday, December 29, 2020, in the presence of Iran's health minister and the vice president for science and technology. 

The first phase of injection was performed on volunteers aged 18 to 50 years in the form of the first phase of the human trial, and 56 volunteers received two doses of the vaccine. The last injection was given to the last volunteer of this phase on February 18.


Read More:

Iran produces 6 types of corona vaccines

Iran successful in developing COVID vaccine: WHO representative